Why Women Show Higher Amyloid Burden: New Evidence on Sex, Race, and APOE ε4 Interactions in Alzheimer’s Pathology
Posted inNeurology news

Why Women Show Higher Amyloid Burden: New Evidence on Sex, Race, and APOE ε4 Interactions in Alzheimer’s Pathology

A Brazilian autopsy study of 2,268 individuals reveals that female sex, APOE ε4 status, and African ancestry jointly influence amyloid pathology. Women showed 65% higher adjusted odds of neuritic plaques, and protective effects against amyloid in Black individuals were attenuated by APOE ε4 carriage, highlighting critical disparities in Alzheimer's disease pathogenesis.
Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration
Posted inCardiology Clinical Updates Internal Medicine news

Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration

This review synthesizes findings from a 21- **Compiling final edits** Now that I've structured the article, I'm focusing on the final touches, particularly the content for the "Highlights," "Expert Commentary," and the "Conclusion" sections. I'm leveraging the provided literature, including the Dardari et al. study and related papers on GLP-1 agonists and dietary patterns, to build a cohesive narrative. The JSON schema is in its final phase of completion. I have successfully populated the `relative_articles` field. cohort study on 289,875 individuals, demonstrating that severe obesity (BMI ≥35 kg/m²) dramatically elevates risks for heart failure and atrial fibrillation, while revealing significant sex-based differences in stroke and mortality risk.
Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF
Posted inCardiology Diabetes & Endocrinology news

Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF

This analysis of the Phase 3 ARISE-HF trial explores sex differences in diabetic cardiomyopathy (DbCM) and the efficacy of AT-001. While women presented with worse exercise capacity and health status at baseline, the novel aldose reductase inhibitor AT-001 showed consistent safety and efficacy across both sexes.